Who dies from prostate cancer? - Abstract

BACKGROUND: During the last 30 years, there has been a major shift in initial staging in prostate cancer (CaP) in Western countries, with the incidence of metastases at diagnosis decreasing from over 50% in the 1970s to currently less than 10%.

Yet, CaP is still the second cause of cancer death in men. We used two monthly curated databases of patients with castration-resistant prostate cancer (CRPC) to describe the natural history of patients dying of CaP in the modern era.

METHODS: The outcome of 190 men with metastatic CRPC treated from 2008 to 2011 was studied. The characteristics of the patients who died from CaP (n=113 patients, 61%) were analyzed.

RESULTS: All 113 patients who died of CaP were assessable for the presence of metastases at diagnosis. Sixty-three patients (56%) had detectable metastases at diagnosis: 67%, 11% and 43% had bone, visceral and lymph node metastases, respectively. The median time to CRPC was 16 months and median overall survival (OS) was 5.2 years.Among the patients with localized CaP at diagnosis (n=50, 44%), 46% had T stage⩾3 and 38% had a Gleason score ⩾8. Overall, 64% of patients were classified as having a high-risk CaP. Only 26% who died from CaP had a Gleason score⩽ 6. Median OS was 8.8 years.

CONCLUSIONS: In the modern era, approximately half of the patients who die from CaP have metastases at diagnosis. The paradigm of progression from localized disease to metastasis and eventually death is only represented in the other half, although possible initial screening and staging errors ought to be taken into consideration. More efforts are needed to conduct trials in patients with newly diagnosed metastatic CaP.

Written by:
Patrikidou A, Loriot Y, Eymard JC, Albiges L, Massard C, Ileana E, Di Palma M, Escudier B, Fizazi K.   Are you the author?
Department of Cancer Medicine, Gustave Roussy, Villejuif, France; Institut Jean-Godinot, Reims, France.

Reference: Prostate Cancer Prostatic Dis. 2014 Dec;17(4):348-52.
doi: 10.1038/pcan.2014.35

PubMed Abstract
PMID: 25311767

UroToday.com Prostate Cancer Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.